Middle East & North Africa | Prevalence of HIV, female (% ages 15-24)

Prevalence of HIV, female is the percentage of females who are infected with HIV. Youth rates are as a percentage of the relevant age group. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source
Middle East & North Africa | Prevalence of HIV, female (% ages 15-24)
1960
1961
1962
1963
1964
1965
1966
1967
1968
1969
1970
1971
1972
1973
1974
1975
1976
1977
1978
1979
1980
1981
1982
1983
1984
1985
1986
1987
1988
1989
1990 0.1
1991 0.1
1992 0.10029941
1993 0.10086604
1994 0.10144048
1995 0.10225822
1996 0.10335924
1997 0.1045032
1998 0.1056799
1999 0.10623728
2000 0.10646542
2001 0.10585939
2002 0.10528509
2003 0.1041198
2004 0.10323223
2005 0.1023992
2006 0.1018701
2007 0.10134995
2008 0.10110025
2009 0.10084729
2010 0.10058115
2011 0.10060073
2012 0.10062269
2013 0.1006458
2014 0.10033475
2015 0.10034563
2016 0.10035533
2017 0.10036427
2018 0.10037152
2019 0.10037596
2020 0.10037864
2021 0.10037936
2022

Middle East & North Africa | Prevalence of HIV, female (% ages 15-24)

Prevalence of HIV, female is the percentage of females who are infected with HIV. Youth rates are as a percentage of the relevant age group. Limitations and exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information. Statistical concept and methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.
Publisher
The World Bank
Origin
Middle East & North Africa
Records
63
Source